The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) of Beth Israel Deaconess Medical Center suggest maturation of B-cell response without further boosting. 1.1.7), Beta (B.1.351),

Immune Response 52

Immune Response Medicine Vaccination Vaccine 52

Pharmaceutical Technology

FEBRUARY 3, 2023

Additionally, advances in the study of broadly neutralising antibodies (bNAbs) have led to new candidates being studied in early trials. The study was done in collaboration with the United States Army Medical Research and Development Command (USAMRDC), the Thai Ministry of Health, and others.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Delveinsight

AUGUST 6, 2020

By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus. Scientists have already isolated many highly potent neutralizing antibodies from patients who recovered from COVID-19. FDA turns back peanut allergy patch of DBV Technologies. The agency raised no safety concerns.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

Pharmaceutical Technology

JUNE 8, 2023

The company’s samRNA vector is based on a synthetic RNA molecule derived from a wild-type Venezuelan Equine Encephalitis Virus (VEEV) replicon with the goal of extending the duration and magnitude of immunogen expression to drive potent and durable immune responses. The samRNA is delivered in a lipid nanoparticle (LNP) formulation.

Vaccination 130

Vaccination Vaccine Immune Response Allergies 130

Scienmag

MAY 13, 2021

New study suggests COVID vaccines may still be helpful for patients with antibody deficiency disorders According to data from a cohort of adult and pediatric patients with antibody deficiencies, patients that often fail to make protective immune responses to infections and vaccinations showed robust T-cell activity and humoral immunity against SARS-CoV-2 (..)

Immune Response 53

Immune Response Antibody Protein Vaccination 53

Scienmag

AUGUST 21, 2020

While antibodies may fade fast, T cells appear to be long-lived and might confer lasting immunity.

Immune Response 40

Immune Response Antibody Scientist Allergies 40

XTalks

JANUARY 20, 2021

Researchers at KU Leuven in Belgium have found a potential mechanism underlying irritable bowel syndrome (IBS) that involves activation of immune cells primed by past gastrointestinal infections. However, IBS patients do not have allergies to any given foods, nor any gastrointestinal conditions, such as celiac disease.

Immune Response 52

Immune Response Research Allergies Protein 52

Scienmag

DECEMBER 22, 2020

Study provides insights that could inform vaccine timing and improve care BOSTON — Pregnant women may be especially vulnerable to developing more severe cases of COVID-19 following SARS-CoV-2 infection, but little is known about their anti-SARS-CoV-2 immune response or how it may affect their offspring.

Immune Response 40

Immune Response Antibody Vaccination Vaccine 40

Scienmag

NOVEMBER 6, 2020

New study demonstrates candidate’s potential to generate antibodies, limit viral shedding Credit: Craig Chandler, University of Nebraska-Lincoln A genetically edited form of a herpes simplex virus — rewired to keep it from taking refuge in the nervous system and eluding an immune response — has outperformed a leading vaccine candidate (..)

Vaccination 49

Vaccination Vaccine Immune Response Genetics 49

The Pharma Data

MARCH 13, 2022

That’s because the mutations that led to the variant’s emergence aren’t found in the regions of the virus that stimulates one type of cellular immune response, says an international research team from Johns Hopkins Medicine, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and ImmunoScape, a U.S.-Singapore

Immune Response 52

Immune Response Protein Medicine Genetics 52

Scienmag

NOVEMBER 17, 2020

New research published in Arthritis & Rheumatology suggests that immune responses to certain bacteria that cause periodontal disease may play a role in patients’ higher cardiovascular disease risk. Among 197 patients with rheumatoid arthritis, those with antibody responses to common […].

Immune Response 40

Immune Response Bacteria Antibody Research 40

XTalks

AUGUST 16, 2021

Immune systems can be weakened in individuals with HIV/AIDS; cancer and transplant patients taking certain immunosuppressive drugs; and those with genetic diseases affecting the immune system like congenital agammaglobulinemia and congenital IgA deficiency. Related: CDC Backs J&J COVID-19 Shot Amid GBS and Delta Variant Concerns.

Vaccination 85

Vaccination Vaccine Antibody Immune Response 85

pharmaphorum

SEPTEMBER 29, 2022

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain.

Drugs 69

Drugs Immune Response Allergies Sales 69

The Pharma Data

JULY 8, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., variant. .” 1.351), the Gamma (P.1)

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

XTalks

NOVEMBER 30, 2023

Preclinical data demonstrated that HB-500 was well-tolerated, eliciting robust, high-quality and enduring immune responses, including antigen-specific T cells and antibodies, in non-human primates. In November 2023, Hookipa Pharma Inc., Notably, it significantly reduced viral load and clinical illness compared to a placebo.

FDA Approval 108

FDA Approval Gene Therapy Clinical Trials Clinical Trials 108

The Pharma Data

JULY 6, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

OCTOBER 26, 2020

Diagnostics Update : To-date the FDA has authorized 284 individual EUAs, which include 221 molecular tests, 56 antibody tests and 7 antigen tests. . Only a fraction of intravenous antibody treatments will make their way to the lungs of COVID-19 patients, which is where the infection is primarily located. Please read more here. .

Antibody 52

Antibody Vaccination Vaccine Manufacturing 52

Delveinsight

JANUARY 21, 2021

Eli Lilly, via its Loxo Oncology biotech unit, is enlisting to a three-therapy pact with Merus concentrated on T-cell redirecting bispecific antibody work. These will come out of Merus’ so-called Biclonics platform that develops CD3-engaging, T-cell redirecting bispecific antibody therapies. billion in total for three drugs.

Research 52

Research Protein Clinical Trials Clinical Trials 52

pharmaphorum

JULY 7, 2022

Once the pandemic hit, Moderna teamed up with the US National Institute of Allergy and Infectious Diseases (NIAID) to co-develop the former’s vaccine. One such company is Vir Biotechnology, which has a pipeline of antibodies and siRNA therapeutics against COVID-19, hepatitis B and D, influenza, and HIV. Identifying the threat.

Vaccination 104

Vaccination Vaccine Development Research 104

The Pharma Data

JUNE 25, 2021

The CDC has defined Variant of Interest (VoI) as a variant with genetic markers that have been associated with changes to receptor binding, reduced neutralization by antibodies generated against previous infection or vaccination, or predicted increase in transmissibility or disease severity. BARDA is providing up to $1.75 About NVX-CoV2373.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

The Pharma Data

DECEMBER 23, 2020

Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0 mg and 2.0 The 1.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

XTalks

MAY 2, 2024

Some treatments already on the market have grabbed additional approvals in 2024, including Novo Nordisk’s Wegovy (semaglutide) for cardiovascular risk reduction, Dupixent (dupilumab) for eosinophilic esophagitis (EoE) in young children and Xolair (omalizumab) for food allergies. It is also entering late into the market.

Drugs 52

Drugs FDA Approval Vaccination Vaccine 52

The Pharma Data

NOVEMBER 17, 2020

It currently has several vaccines in its pipeline, among which are the HIV-1/AIDS, intra-nasal Influenza and malaria, and collaborative projects in the field of allergy immunotherapy and in oncology. ” About Mymetics. For further information, please visit www.mymetics.com. Forward looking statements.

Vaccination 40

Vaccination Vaccine Containment Development 40

Pfizer

JULY 26, 2022

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. IMPORTANT SAFETY INFORMATION . has a fever.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

The Pharma Data

JANUARY 29, 2021

1.351 and P1, respectively — contain a mutation called E484K, “which results in changes in the shape of the virus spike protein such that neutralizing antibodies might not bind as well as it does in the absence of the mutation,” explained Dr. Jay Butler, deputy director for infectious diseases at the U.S.

Vaccination 52

Vaccination Vaccine Antibody Immune Response 52

The Pharma Data

APRIL 27, 2021

to €283 million, reflecting growth of Digestive and Mental Wellness categories as well as Allergy partially offset by the decline of the Pain category. Development for Dupixent ® for grass allergy has been discontinued. At CER, BOI increased 48.6%. The ratio of BOI to net sales was 40.5% (and 27.5% Consumer Healthcare. Change at CER.

Sales 52

Sales Vaccination Vaccine Medicine 52

The Pharma Data

APRIL 28, 2021

About Dupixent Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. BTK is involved in innate and adaptive immune responses and is a signaling molecule in immune mediated diseases.

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

Pfizer

NOVEMBER 2, 2022

The influenza virus is subject to constant mutations to evade the host immune response, causing a seasonal variation in circulating strains. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. are immunocompromised or are on a medicine that affects the immune system.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

pharmaphorum

JULY 26, 2022

Earlier this year , the US National Institute of Allergy and Infectious Disease (NIAID), announced that it had begun a phase 1 clinical trial evaluating three mRNA vaccines against HIV that were developed alongside Moderna.

Gene Therapy 140

Gene Therapy Protein Vaccination Vaccine 140

The Pharma Data

JULY 8, 2021

“We are proud to advance an innovative, first-in-class monoclonal antibody that targets the top of the inflammatory cascade and represents a potentially transformative treatment option for a broad population of patients with severe asthma. Ann Allergy Asthma Immunol. World Allergy Organization (WAO). EMJ Allergy Immunol.

Allergies 52

Allergies Trials In-Vivo Medicine 52

The Pharma Data

NOVEMBER 9, 2020

About Tezepelumab Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. 10 World Allergy Organization (WAO). 11 Busse WW.

Trials 52

Trials Production Sales Manufacturing 52

Pfizer

JULY 19, 2022

The companies’ previously announced safety, tolerability and immunogenicity data from a Phase 2/3 trial that found a 30 µg booster dose of the Omicron-adapted bivalent vaccine candidate elicited a superior immune response against Omicron BA.1 is immunocompromised or are on a medicine that affects the immune system. has a fever.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

Pfizer

JULY 8, 2022

Following a third dose in this age group , the vaccine was found to elicit a strong immune response, with a favorable safety profile similar to placebo. IMPORTANT SAFETY INFORMATION Tell your vaccination provider about all the vaccine recipient’s medical conditions, including if the vaccine recipient: has any allergies.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

The Pharma Data

DECEMBER 21, 2020

About Tezepelumab Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. J Allergy Clin Immunol. Outside the U.S.,

Trials 40

Trials Production Sales Manufacturing 40

Pfizer

JULY 8, 2022

A two-dose primary series of the vaccine (30-µg dose) elicited SARS-CoV-2–neutralizing antibody geometric mean titers (GMTs) of 1,239.5, Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. are immunocompromised or are on a medicine that affects the immune system.

FDA Approval 102

FDA Approval Vaccination Vaccine Clinical Trials 102

The Pharma Data

FEBRUARY 8, 2021

Allergy Cough & Cold. to €238 million, reflecting growth in the Allergy (Allegra ® and Xyzal ® ) and Digestives categories. sales decreased 1.6%, reflecting the impact of the Zantac ® recall which offset the growth in the Allergy and Nutritionals categories. Full-year 2020, BOI of Vaccines increased 4.4% (up 11.2%

Sales 52

Sales Vaccine Vaccination Production 52